Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide + NNC0480-0389 dose-finding study in type 2 diabetes
2020-004863-14Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semaglutide and NNC0480-0389 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Jul 2021; status: completed.
02
Drugs
semaglutideNNC0480-0389
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2020-004863-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004863-14.